At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
In Brief
A Phase 3 clinical trial evaluating Baxdrostat and Placebo for Resistant Hypertension. Completed, enrolled 218 participants across 102 sites in 22 countries.
Detailed Summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Study Details
Timeline
Interventions
Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: • 2 mg per tablet.
Placebo tablet matching baxdrostat, administered orally, once daily (QD).